Histology

COTA Wins Google Cloud Customer of the Year Award for Using AI to Improve Cancer Care

Retrieved on: 
Tuesday, August 29, 2023

COTA was recognized for its achievements in the Google Cloud ecosystem and is building a series of new AI and natural language processing (NLP) models tailored to unstructured oncology data.

Key Points: 
  • COTA was recognized for its achievements in the Google Cloud ecosystem and is building a series of new AI and natural language processing (NLP) models tailored to unstructured oncology data.
  • The ultimate goal of this work is to ensure that all patients receive high-quality care regardless of who they are or where they live.
  • With AI, we can dramatically accelerate the process of creating high-quality data responsibly so that we can uncover disparities and improve cancer treatment," Miruna Sasu, President and CEO, COTA.
  • COTA is tackling this challenge head-on, with the goal of fueling a new era of data-driven cancer care.

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

Retrieved on: 
Monday, August 28, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year.
  • The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.
  • Akero plans to hold an investor webcast detailing the findings.

Histolix Appoints Jane Elizabeth Brock, MBBS, Ph.D. to Board of Directors

Retrieved on: 
Tuesday, August 22, 2023

SACRAMENTO, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, today announced the appointment of Jane Elizabeth Brock, MBBS, Ph.D. to the company's board of directors. Brock brings more than 20 years of experience in pathology and is a specialist in diagnostic breast oncology. She is currently the chief of Breast Pathology Division, Brigham and Women's Hospital in Boston, and associate professor of Pathology at Harvard Medical School.

Key Points: 
  • SACRAMENTO, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, today announced the appointment of Jane Elizabeth Brock, MBBS, Ph.D. to the company's board of directors.
  • "Her vast background in pathology will help our ongoing endeavors to streamline histology procedures, helping shorten diagnostic pathology procedure outcomes from days to minutes.
  • She brings a wealth of knowledge to our highly esteemed clinical team currently working on this revolutionary digital pathology solution."
  • "The Histolix team is extremely well qualified to enable the next generation pathology solutions and ensure excellence in patient care."

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Retrieved on: 
Thursday, August 17, 2023

JERUSALEM, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated Alpha DaRT across four prospective trials conducted at several international institutions.

Key Points: 
  • JERUSALEM, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated Alpha DaRT across four prospective trials conducted at several international institutions.
  • Between February 2017 and December 2022, 81 lesions in 71 patients were treated with Alpha DaRT in four prospective feasibility trials whose objective was to assess early toxicity and tumor response outcomes.
  • There was no grade 2 or higher late toxicities observed in this cohort, defined as toxicities occurring six months or later after Alpha DaRT treatment.
  • “We are excited to share these longer-term data on outcomes from treatment with Alpha DaRT,” noted Uzi Sofer, Alpha Tau’s CEO.

Dr. Zachary Johnson Joins Dallas Neurosurgical & Spine

Retrieved on: 
Wednesday, August 16, 2023

PLANO, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Zachary D. Johnson, MD, a fellowship-trained neurosurgeon, has joined Dallas Neurosurgical & Spine.

Key Points: 
  • PLANO, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Zachary D. Johnson, MD, a fellowship-trained neurosurgeon, has joined Dallas Neurosurgical & Spine.
  • “At Dallas Neurosurgical & Spine, our goal is to perform the least invasive, most effective procedure available, specifically tailored for each individual patient and their unique needs, and Dr. Johnson shares that care philosophy,” said Jeremy Denning, MD, a neurosurgeon with Dallas Neurosurgical & Spine.
  • Following medical school, Dr. Johnson completed both his residency in neurosurgery and a spine surgery fellowship at UT Southwestern Medical Center in Dallas.
  • Dallas Neurosurgical & Spine is the longest-running, privately held neurosurgical group in North Texas, with more than 50 years of experience caring for patients.

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2023 and provided business updates.

Key Points: 
  • “These results add to the growing body of evidence supporting the ongoing clinical development of EFX and its potential as a transformative NASH therapy.
  • Akero remains on track to report Week 36 results of the Phase 2b SYMMETRY main study in adult patients with cirrhotic NASH (F4, compensated) in the fourth quarter of 2023.
  • Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended June 30, 2023 were $658.9 million.
  • Total operating expenses were $35.6 million for the three-month period ended June 30, 2023, compared to $27.6 million for the comparable period in 2022.

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023

SAN FRANCISCO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • The data were simultaneously presented in a late-breaking oral session at the EASL Congress 2023 in Vienna, Austria and were also selected for inclusion in the Best of EASL Congress summary.
  • The Company intends to meet with the U.S. Food and Drug Administration in the second half of 2023 and to pursue European Union scientific advice in parallel.
  • As of June 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $478.0 million.
  • 89bio reported a net loss of $38.4 million for the three months ended June 30, 2023, compared to a net loss of $25.1 million for the three months ended June 30, 2022.

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 7, 2023

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

Key Points: 
  • “We have significantly advanced our pipeline since the first quarter, including bringing two novel agents into phase 1/2 clinical trials.
  • Alan plans to start a new company outside of our focus, which will incubate in Tango labs, facilitating his advisor role to Tango.
  • Alan played a pivotal role founding Tango and has been an integral part of the Company from inception.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Histologics LLC, Announces Jannalee Johnson, Business Development Consultant for Gynecologic and Wound Care Expansion

Retrieved on: 
Friday, August 4, 2023

ANAHEIM, Calif., Aug. 4, 2023 /PRNewswire/ -- Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care, effective Monday, July 24th, 2023.  With a remarkable track record spanning over 15 years in the laboratory industry, Ms. Johnson brings a wealth of experience and expertise to further strengthen Histologics' position as a premier innovator in the diagnostic, gynecologic, and wound care sectors.  Ms. Johnson's impressive career journey includes holding the position of Vice President of Sales at a prominent national women's health laboratory.  During her tenure, she played a pivotal role in negotiating an exclusive contract for a biopsy device solely for the company to market in the North America and United Kingdom, expanded the company's market reach and establishing key strategic partnerships. Most recently she held the position of Senior Product Manager and Marketing Manager at XiFin, Inc., exemplifying her ability to develop innovative solutions tailored to meet the evolving needs of healthcare professionals and patients.

Key Points: 
  • ANAHEIM, Calif., Aug. 4, 2023 /PRNewswire/ -- Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care , effective Monday, July 24th, 2023.
  • "Her extensive experience in the laboratory and healthcare industry, coupled with her remarkable achievements, makes her the perfect fit to lead our Business Development efforts in the Gynecologic and Wound Care segments.
  • We are confident that under her guidance, we will continue to grow our worldwide footprint in our gynecologic and wound care divisions."
  • In her new role, Ms. Johnson will be responsible for fostering strategic partnerships, identifying business opportunities, and driving growth in the Gynecologic and Wound Care sectors worldwide.

Osteopathic Medicine School (VCOM)-Louisiana Makes EnChroma Glasses Available to Color Blind Students on Campus

Retrieved on: 
Monday, July 31, 2023

MONROE, La., and BERKELEY, Calif., July 31st, 2023 /PRNewswire-PRWeb/ -- – VCOM is the First College in Louisiana to Address the Learning Challenges for Color Blind Students and Faculty by Teaming with EnChroma –

Key Points: 
  • It is the first college and medical program in Louisiana to support color blind students and faculty by working with EnChroma.
  • EnChroma – creators of glasses for color blindness – and the Edward Via College of Osteopathic Medicine (VCOM)-Louisiana – today announced that special EnChroma glasses for color blindness will be available for students, faculty and staff who are Color Vision Deficient (CVD) to borrow on campus to help them better navigate schoolwork that requires identifying and understanding colors.
  • While people with normal color vision see over one million shades of color, the color blind only see an estimated 10% of hues and shades.
  • VCOM joins numerous other renowned universities that offer EnChroma glasses to color blind students to borrow as part of the EnChroma Color Accessibility Program™ for Education.